🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

114 results for “GT” Clear

  1. GTAEXS617

    RECURSION PHARMACEUTICALS, INC.

    Head and Neck Squamous Cell Carcinoma (HNSCC)

    phase 2 small molecule active

    1 trial

  2. GTB-3550 TriKE® Phase I

    GT Biopharma

    High-risk Myelodysplastic Syndromes

    phase 2 small molecule terminated

    1 trial

  3. GTI-2040

    Aptose Biosciences

    Carcinoma, Renal Cell

    phase 2 small molecule completed

    1 trial

  4. GTI-2040

    Aptose Biosciences

    Acute Myeloid Leukemia

    phase 2 mab completed

    1 trial

  5. GTS-21

    BRIGHT MINDS BIOSCIENCES INC.

    Tobacco Use Disorder

    phase 2 small molecule terminated

    1 trial

  6. GTX-102, GTX/UX Diluent and Flush Solution

    Lacuna Pharma Pty Ltd

    Angelman Syndrome

    phase 2 small molecule active

    1 trial

  7. Glycosides Of Tripterygium Wilfordii Hook(GTW)

    The First People's Hospital of Lianyungang

    Henoch-Schönlein Purpura Nephritis

    phase 2 small molecule active

    1 trial

  8. HGT-1110

    Takeda

    Metachromatic Leukodystrophy (MLD)

    phase 2 mab completed

    1 trial

  9. HGT-1111

    Takeda

    Late Infantile Metachromatic Leukodystrophy

    phase 2 small molecule terminated

    1 trial

  10. HGT-1410

    Takeda

    Sanfilippo Syndrome

    phase 2 small molecule terminated

    1 trial

  11. Homoharringtonine

    Teva Pharma GmbH

    Myeloid Leukemia, Chronic

    phase 2 small molecule terminated

    1 trial

  12. IONIS-AGT-LRx

    IONIS PHARMACEUTICALS INC

    Chronic Heart Failure With Reduced Ejection Fraction

    phase 2 small molecule completed

    1 trial

  13. ISIS 443139 10 mg

    IONIS PHARMACEUTICALS INC

    Huntington's Disease

    phase 2 small molecule completed

    1 trial

  14. Jiangtang Tiaozhi recipe

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Type2 Diabetes

    phase 2 small molecule active

    1 trial

  15. Laquinimod

    Teva Pharma GmbH

    Huntington's Disease

    phase 2 small molecule completed

    1 trial

  16. Letrozole SanoSwiss 2,5 mg plėvele dengtos tabletės

    Pfizer Australia Pty Ltd

    HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE BREAST CANCER

    phase 2 small molecule active

    1 trial

  17. Low Dose GT-02287

    Gain Therapeutics

    Parkinson Disease

    phase 2 small molecule active

    1 trial

  18. MDGN201 TARGTEPO

    Avalo Therapeutics

    Anemia of End Stage Renal Disease

    phase 2 mab terminated

    1 trial

  19. PPY988A

    Novartis Pharmaceuticals

    Geographic atrophy (GA) secondary to age-related macular degeneration (AMD) in participants already treated with GT005 in the previous studies GT005-01 (FOCUS), GT005-02 (EXPLORE) and GT005-03 (HORIZON).

    phase 2 small molecule active

    1 trial

  20. PTC518

    PTC THERAPEUTICS, INC.

    Huntington Disease

    phase 2 small molecule completed

    1 trial

  21. Placebo to match 5-mg PTC518 tablets, Placebo to match 20-mg PTC518 tablets, PTC518, PTC518

    PTC THERAPEUTICS, INC.

    Huntington’s Disease

    phase 2 small molecule active

    1 trial

  22. Quadriceps strength training

    Hospital Authority, Hong Kong

    Patellofemoral Pain Syndrome

    phase 2 other active

    1 trial

  23. RO7234292, RO7234292 Placebo

    Hoffmann-La Roche

    Prodromal and Early Manifest Huntington’s Disease

    phase 2 small molecule active

    1 trial

  24. SAGE-718

    SUPERNUS PHARMACEUTICALS, INC.

    Huntington Disease

    phase 2 small molecule completed

    2 trials

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources